Ashland Inc. (AHT.F)
| Previous close | 88.50 |
| Open | 90.00 |
| Bid | 91.00 x N/A |
| Ask | 92.00 x N/A |
| Day's range | 90.00 - 90.00 |
| 52-week range | 65.50 - 90.00 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 4.613B |
| Beta (5Y monthly) | 0.92 |
| PE ratio (TTM) | 26.79 |
| EPS (TTM) | 3.36 |
| Earnings date | 23 July 2024 - 29 July 2024 |
| Forward dividend & yield | 1.42 (1.60%) |
| Ex-dividend date | 29 Feb 2024 |
| 1y target est | 104.00 |
Business WireTurnspire Capital Partners to Acquire Ashland Nutraceuticals Business
NEW YORK, May 07, 2024--Turnspire Capital Partners LLC ("Turnspire") announced today that an affiliate has signed a definitive agreement to acquire the nutraceuticals business of Ashland Inc. (NYSE: ASH) ("Ashland Nutraceuticals" or the "Business").
GlobeNewswireAshland signs definitive agreement to sell nutraceuticals business to Turnspire Capital Partners
WILMINGTON, Del., May 07, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) announced today that it has signed a definitive agreement to sell its nutraceuticals business to Turnspire Capital Partners LLC (“Turnspire”). The transaction is expected to close in the calendar third quarter 2024, subject to the satisfaction of customary closing conditions. Ashland's nutraceuticals business supplies a broad portfolio of active ingredients and formulation aids to nutritional product companies, as well a
ZacksIs Ashland Inc. (ASH) Stock Outpacing Its Basic Materials Peers This Year?
Here is how Ashland (ASH) and Buenaventura (BVN) have performed compared to their sector so far this year.
